 |
97 Diseases |  |
247 Trials |
|
247 Trials |  |
14602 News |  |
| «12...149150151152153154155156157158159...170171» |
- || Xarelto (rivaroxaban) / Bayer, J&J
83 yo prior CABG (2006), pacemaker for CHB (2010), paroxysmal Afib (<10% burden) on rivaroxaban. Good GDMT. Very active, asymptomatic. Continue ASA 81 mg? @fischman_david @DocSavageTJU @ajaykirtane @rwyeh @KaulP @DrMarthaGulati @mmamas1973 (Twitter) - Apr 1, 2019
- || Xarelto (rivaroxaban) / Bayer, J&J
Ya voté! Si tiene ritmo sinusal no lo anticoagularia (+riesgos q beneficios)... WASH, WATCH, WARCEF, etc, COMMANDER HF con Rivaroxaban... Igualmente no debe ser igual FEy 22% que 35% (personalize medicine??)... q opinan uds? (Twitter) - Apr 1, 2019
- |||| Xarelto (rivaroxaban) / Bayer, J&J
Clinical: How does Rivaroxaban's chemical efficacy treat fibrin platelet thrombi/blood clots anchored/occluding systemic venous/arterial networks in living ppl? Detail how Care Excellence Guidelines caters for DVT, Prevention & Recurring DVT➡️PE prior to stress exertion & impact pressure? (Twitter) - Apr 1, 2019
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Enrollment change, Surgery: Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation (clinicaltrials.gov) - Apr 1, 2019
P3, N=300, Not yet recruiting, Sponsor: Massachusetts General Hospital
N=200 --> 300
- | fondaparinux / generics, enoxaparin sodium / generics
Journal: Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty. (Pubmed Central) - Mar 30, 2019
Detailed demographic data were missing from the literature, and we were unable to demonstrate the cause of different reported outcomes between industry-funded and nonfunded studies. Further investigations should be aimed toward understanding how funded studies report less adverse outcomes in analyzing VTE after TJA.
- | Xarelto (rivaroxaban) / Bayer, J&J, Savaysa (edoxaban) / Daiichi Sankyo, Eliquis (apixaban) / BMS
Retrospective data, Journal: Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. (Pubmed Central) - Mar 29, 2019
For apixaban and edoxaban, no distinct change in the overall mortality was simulated by dose modification. This study suggested that the current dose of rivaroxaban might be excessive and would need to be reduced to decrease the excess risk of major bleeding.
- | Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
Clinical, Journal: Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group. (Pubmed Central) - Mar 29, 2019
Our study highlights significant inaccuracies in NOAC prescribing. Patients commenced on NOACs should be assessed and followed up in a multidisciplinary AF clinic to ensure safe and effective prescribing and stroke prevention.
- | Xarelto (rivaroxaban) / Bayer, J&J
Journal: Bayer and Janssen pay $775m to settle Xarelto misinformation claims. (Pubmed Central) - Mar 29, 2019
Patients commenced on NOACs should be assessed and followed up in a multidisciplinary AF clinic to ensure safe and effective prescribing and stroke prevention. No abstract available
- | Xarelto (rivaroxaban) / Bayer, J&J
Retrospective data, Review, Journal: Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) - Mar 29, 2019
Addition of rivaroxaban to the anti-platelet regimen was effective in patients with coronary artery disease, but the safety outcomes were doubtful. Further future trials will be able to completely solve this issue.
- | Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
Preclinical, Journal: In vitro bioaccessibility, bioavailability, and the plasma protein interaction of new oral anticoagulants in presence of macronutrients. (Pubmed Central) - Mar 28, 2019
Further future trials will be able to completely solve this issue. Dabigatran, rivaroxaban and apixaban may be administered independently of a standard meal, provided that it does not include a high amount of dietary fibers.
- | Xarelto (rivaroxaban) / Bayer, J&J, Plavix (clopidogrel) / BMS, Sanofi
Retrospective data, Journal: Effect and safety of antithrombotic therapies for secondary prevention after acute coronary syndrome: a network meta-analysis. (Pubmed Central) - Mar 28, 2019
Treatment with aspirin + new P2Y12 inhibitors reduced all-cause deaths (OR: 0.91, 95% credibility interval: 0.84-0.98) and cardiac death risk (OR: 0.86, 95% credibility interval: 0.79-0.93). We concluded the following from our study: 1) an aspirin + new P2Y12 inhibitor/ clopidogrel conversion treatment strategy was not inferior to aspirin + new P2Y12 inhibitor; 2) compared with aspirin + clopidogrel, the conversion strategy may further reduce the risk of myocardial infarction without increasing the risk of bleeding; and 3) compared with aspirin + clopidogrel, treatment with aspirin + new P2Y12 inhibitors may result in reduced risk of death.
- | Xarelto (rivaroxaban) / Bayer, J&J
Clinical, Journal: Compartment syndrome secondary to an atraumatic gastrocnemius tear in a patient on NOACs: presentation and complications of treatment. (Pubmed Central) - Mar 27, 2019
Acute compartment syndrome is a limb-threatening condition often associated with high-energy injury. We present the case of a man who sustained compartment syndrome secondary to an atraumatic tear in the gastrocnemius muscle and the complications which arose in his treatment due to his being on rivaroxaban.
- | Clinical, Journal: Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation. (Pubmed Central) - Mar 27, 2019
In real-world practice, more than one-third of patients with NOAC prescriptions received an off-label reduced dose, which could result in an increased risk of stroke. Considering the high risk of stroke in these patients, on-label use of NOAC is recommended.
- ||| Xarelto (rivaroxaban) / Bayer, J&J
Clinical: Bayer and J&J ink $775M deal to resolve 25,000 Xarelto cases https://t.co/bnHpq2Xtix (Twitter) - Mar 25, 2019
- ||| Xarelto (rivaroxaban) / Bayer, J&J
M&A: Bayer, Janssen Pharma Reach $775M Agreement to Settle Xarelto Litigation. Settlement to Be Shared Equally Between Companies. $JNJ $BAYRY (Twitter) - Mar 25, 2019
- |||| Xarelto (rivaroxaban) / Bayer, J&J
Interview: CRT 2019 @CMichaelGibson giving a brilliant interview on Rivaroxaban 2.5mg BID combined with DAPT at @CRT_meeting @Bayer #Xarelto #Rivaroxaban #CRT2019 #Cardioed #cardiotwitter #Cardiology #MedEd https://t.co/FrLGoWRVoW via @YouTube (Twitter) - Mar 25, 2019
- | enoxaparin sodium / generics
Clinical, Journal: Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients. (Pubmed Central) - Mar 25, 2019
A recent trial of a new direct factor Xa inhibitor, betrixaban, demonstrated a reduction in VTE events with extended prophylaxis, without significantly increasing the risk of major bleeding. Understanding appropriate patient selection, dosing, and outcomes associated with betrixaban will be important to potentially reducing the continued risk of VTE in patients with acute medical illness.
- | rivaroxaban / Generic mfg.
Retrospective data, Review, Journal, Real-world evidence: Systematic Review and Meta-Analysis of Real-World Studies Evaluating Rivaroxaban for Cancer-Associated Venous Thrombosis. (Pubmed Central) - Mar 25, 2019
The pooled incidence for mortality was lower than reported in many anticoagulation CAT trials. This may suggest that rivaroxaban is being used in CAT patients who have less severe cancer.
- |||||| rivaroxaban / Generic mfg.
New trial, Real-world evidence, Real-world: XARIN: A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF) (clinicaltrials.gov) - Mar 25, 2019
P, N=1000, Not yet recruiting, Sponsor: Bayer
- | Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
Clinical, Journal: Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion. (Pubmed Central) - Mar 23, 2019
In logistic regression analysis neither oral anticoagulation regimen predicted LAA thrombus in TOE whereas maximal LAA emptying velocity was the only parameter independently associated with the presence of thrombus. CONCLUSIONS In the studied group, the choice of anticoagulation didn't depend on patients' thromboembolic or bleeding risk.
- | rivaroxaban / Generic mfg.
Clinical, Journal: Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism. (Pubmed Central) - Mar 23, 2019
Major bleeding was non-significantly reduced at 3-months (HR 0.77, 95% CI 0.57-1.06) and significantly reduced at 6-months (HR 0.68, 95% CI 0.53-0.88) with rivaroxaban. Rivaroxaban reduces recurrent VTE and major bleeding risk versus warfarin in provoked VTE patients treated in routine practice.
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
Clinical, Journal, Real-world evidence: Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review. (Pubmed Central) - Mar 23, 2019
Expert commentary Overall, the RWE studies were aligned with the Phase 3 trials. However, conflicting results were reported for several outcomes of interest.
- | Xarelto (rivaroxaban) / Bayer, J&J
PK/PD data, Journal: Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban. (Pubmed Central) - Mar 22, 2019
The slope of prothrombin time vs. rivaroxaban plasma concentration in rats was retrospectively found to be insensitive by about 5.4-fold compared to than in humans. More than a 67% dose reduction in rivaroxaban is suggested in terms of both a pharmacokinetic point of view, and the sensitivity differences on the prolongation of prothrombin time when used concomitantly with verapamil.
- || rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
Enrollment closed, Adverse events: SiERRA UK: Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice (clinicaltrials.gov) - Mar 20, 2019
P=N/A, N=40000, Active, not recruiting, Sponsor: Bayer
More than a 67% dose reduction in rivaroxaban is suggested in terms of both a pharmacokinetic point of view, and the sensitivity differences on the prolongation of prothrombin time when used concomitantly with verapamil. Not yet recruiting --> Active, not recruiting
- ||||||| rivaroxaban / Generic mfg.
Trial completion: GALILEO-4D: Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) (clinicaltrials.gov) - Mar 19, 2019
P3, N=232, Completed, Sponsor: ECRI bv
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Trial initiation date: A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation (clinicaltrials.gov) - Mar 19, 2019
P=N/A, N=80, Not yet recruiting, Sponsor: The Second Affiliated Hospital of Chongqing Medical University
Active, not recruiting --> Completed Initiation date: Jan 2019 --> Jun 2019
- | rivaroxaban / Generic mfg.
Clinical, Journal: Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure. (Pubmed Central) - Mar 18, 2019
Effectiveness and safety of rivaroxaban vs. warfarin are sustained in NVAF patients with co-morbid HF treated in routine practice. The general consistency between this real-world study and those from phase III randomized trial data of rivaroxaban should provide additional reassurance to clinicians regarding the use of rivaroxaban in NVAF patients with HF.
- | rivaroxaban / Generic mfg.
Clinical, Journal: Rivaroxaban in Patients with Heart Failure. Reply. (Pubmed Central) - Mar 18, 2019
The general consistency between this real-world study and those from phase III randomized trial data of rivaroxaban should provide additional reassurance to clinicians regarding the use of rivaroxaban in NVAF patients with HF. No abstract available
- | Savaysa (edoxaban) / Daiichi Sankyo
Phase classification: OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial (clinicaltrials.gov) - Mar 13, 2019
P=N/A, N=3478, Not yet recruiting, Sponsor: University College, London
No abstract available Phase classification: P4 --> P=N/A
- || pegvorhyaluronidase alfa (PEGPH20) / Halozyme
Trial completion date, Trial primary completion date, Metastases: Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Mar 11, 2019
P=N/A, N=120, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Phase classification: P4 --> P=N/A Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Oct 2019 --> Oct 2020
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date, Surgery: Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation (clinicaltrials.gov) - Mar 11, 2019
P3, N=200, Not yet recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Oct 2019 --> Oct 2020 Trial completion date: Jan 2022 --> May 2022 | Initiation date: Nov 2018 --> Apr 2019 | Trial primary completion date: Nov 2021 --> Apr 2022
- | rivaroxaban / Generic mfg.
Enrollment change: H-REPLACE: Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome (clinicaltrials.gov) - Mar 8, 2019
P4, N=2055, Recruiting, Sponsor: Second Xiangya Hospital of Central South University
Trial completion date: Jan 2022 --> May 2022 | Initiation date: Nov 2018 --> Apr 2019 | Trial primary completion date: Nov 2021 --> Apr 2022 N=3390 --> 2055
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
Clinical, Journal, HEOR: Comparison of Stroke- and Bleed-related Healthcare Resource Utilization and Costs among Patients with Newly Diagnosed Non-Valvular Atrial Fibrillation and Newly Treated with Dabigatran, Rivaroxaban, or Warfarin. (Pubmed Central) - Mar 6, 2019
The results suggest that dabigatran patients had lower bleed-related HCRU and costs than rivaroxaban patients, and lower outpatient stroke-related HCRU, higher bleed-related outpatient HCRU, and lower bleed-related costs than warfarin patients. It provides valuable stroke-related and bleed-related HCRU and costs information among commercially insured and Medicare patients.
- | Tybost (cobicistat) / Gilead, Prezcobix (darunavir/cobicistat) / Gilead, J&J
New P1 trial: CLOTRx: Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers (clinicaltrials.gov) - Mar 6, 2019
P1, N=75, Recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
- | rivaroxaban / Generic mfg.
Clinical, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. (Pubmed Central) - Mar 2, 2019
P3
During the intervention period, rivaroxaban led to a substantially lower incidence of such events, with a low incidence of major bleeding. (Funded by Janssen and others; CASSINI ClinicalTrials.gov number, NCT02555878.).
- || rivaroxaban / Generic mfg., apixaban / Generic mfg.
Trial completion date, Trial primary completion date, Monotherapy: MATHVTE: Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism (clinicaltrials.gov) - Feb 26, 2019
P=N/A, N=850, Recruiting, Sponsor: Indiana University
(Funded by Janssen and others; CASSINI ClinicalTrials.gov number, NCT02555878.). Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
- ||||||| rivaroxaban / Generic mfg.
Trial completion: EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis (clinicaltrials.gov) - Feb 25, 2019
P3, N=499, Completed, Sponsor: Bayer
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Active, not recruiting --> Completed
- |||||| rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
New trial, Adverse events: SiERRA UK: Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice (clinicaltrials.gov) - Feb 20, 2019
P, N=40000, Not yet recruiting, Sponsor: Bayer
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Retrospective data, Journal, HEOR, Real-world evidence: Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. (Pubmed Central) - Feb 19, 2019
Apixaban was associated with a lower risk of ICH than VKAs (HR = 0.41, 95% CI = 0.28-0.60), but was not different to VKAs in terms of IS (HR = 1.01, 95% CI = 0.87-1.17) or non-persistence (HR = 1.08, 95% CI = 0.81-1.45). NOACs appear to be at least as effective and safe as VKAs for stroke prevention in patients with NVAF.
- ||| rivaroxaban / Generic mfg.
Trial completion date, Trial primary completion date: UNIVERSE: Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure (clinicaltrials.gov) - Feb 11, 2019
P3, N=100, Recruiting, Sponsor: Janssen Research & Development, LLC
NOACs appear to be at least as effective and safe as VKAs for stroke prevention in patients with NVAF. Trial completion date: Jan 2022 --> Oct 2020 | Trial primary completion date: Jan 2022 --> Oct 2020
- | rivaroxaban / Generic mfg.
Trial completion, Enrollment change: The Effect of Rivaroxaban in Sickle Cell Disease (clinicaltrials.gov) - Feb 11, 2019
P2, N=14, Completed, Sponsor: University of North Carolina, Chapel Hill
Trial completion date: Jan 2022 --> Oct 2020 | Trial primary completion date: Jan 2022 --> Oct 2020 Enrolling by invitation --> Completed | N=34 --> 14
- | warfarin / Generic mfg.
Trial completion, Enrollment change: Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin) (clinicaltrials.gov) - Feb 8, 2019
P=N/A, N=402764, Completed, Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES
Enrolling by invitation --> Completed | N=34 --> 14 Active, not recruiting --> Completed | N=80000 --> 402764
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Enrollment change: Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs) (clinicaltrials.gov) - Feb 7, 2019
P=N/A, N=227579, Completed, Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES
Active, not recruiting --> Completed | N=80000 --> 402764 N=150000 --> 227579
- ||| rivaroxaban / Generic mfg.
Enrollment open, Combination therapy: Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies (clinicaltrials.gov) - Feb 6, 2019
P4, N=80, Recruiting, Sponsor: University of Florida
N=150000 --> 227579 Not yet recruiting --> Recruiting
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Clinical, Journal: The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. (Pubmed Central) - Feb 2, 2019
The secondary aim is to determine the effect of the pre-procedure interruption on residual anticoagulation when measured by the dilute thrombin time for dabigatran and anti-factor Xa levels for rivaroxaban and apixaban. No abstract available
- | rivaroxaban / Generic mfg.
Journal: Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. (Pubmed Central) - Jan 31, 2019
P=N/A
VLD rivaroxaban reduces thrombus formation and platelet-dependent TG in patients with ACS receiving DAPT, which can be of potential ischemic benefit. This trial was registered at www.clinicaltrials.gov as #NCT01417884.
- || AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Trial completion date, Trial primary completion date: A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects (clinicaltrials.gov) - Jan 30, 2019
P2, N=102, Recruiting, Sponsor: Portola Pharmaceuticals
This trial was registered at www.clinicaltrials.gov as #NCT01417884. Trial completion date: Dec 2018 --> Jan 2020 | Trial primary completion date: Dec 2018 --> Sep 2019
- | rivaroxaban / Generic mfg.
Enrollment open: VaLiDate-R: Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS (clinicaltrials.gov) - Jan 29, 2019
P4, N=150, Recruiting, Sponsor: East and North Hertfordshire NHS Trust
Trial completion date: Dec 2018 --> Jan 2020 | Trial primary completion date: Dec 2018 --> Sep 2019 Not yet recruiting --> Recruiting
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Trial completion: Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients (clinicaltrials.gov) - Jan 28, 2019
P4, N=117, Completed, Sponsor: Onze Lieve Vrouw Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Xarelto (rivaroxaban) / J&J
Trial initiation date: SECRET: Study of Rivaroxaban for CeREbral Venous Thrombosis (clinicaltrials.gov) - Jan 25, 2019
P2, N=380, Not yet recruiting, Sponsor: University of British Columbia
Recruiting --> Completed Initiation date: Oct 2018 --> Mar 2019